THROMBATE III is an effective choice1

In clinical studies, THROMBATE III was proven effective for patients with hereditary antithrombin deficiency (HATD) and for the treatment and prevention of thromboembolism, including before, during, and after surgery and childbirth.1

In patients with hereditary AT deficiency, THROMBATE III is designed to prevent the expansion of a formed thrombus (clot) and formation of additional clots
Fact+Sheet+-+Pregnancy.pdf+%2B%20PI.pdf

Antithrombin (AT) and pregnancy fact sheet

Up to 70% of pregnant women with HATD who do not receive prophylaxis may experience thromboembolic complications.2,3 Download the AT and pregnancy fact sheet and see how THROMBATE III directly prevents and treats thromboembolism in patients with HATD during pregnancy, childbirth, and after delivery.

Fact+Sheet_surgical.pdf+%2B%20PI.pdf

THROMBATE III and surgical procedures fact sheet

Venous thromboembolism impacts thousands of medical and surgical patients each year.1

Download the THROMBATE III and surgical procedures fact sheet to see how an AT replacement therapy like THROMBATE III is a direct approach to managing HATD in high-risk situations.

THROMBATE III replaces the AT that is missing1

  • THROMBATE III helps prevent and treat thromboembolism during surgery in patients with HATD1
An AT replacement therapy like THROMBATE III is a direct approach to managing hereditary AT deficiency in high-risk situations

In clinical studies, the most common adverse reactions (≥ 5% of subjects) were dizziness, chest discomfort, nausea, dysgeusia, and pain (cramps).

Fact+sheet+-+THROMBATE+and+FFP.pdf+%2B%20PI.pdf

The properties of THROMBATE III and fresh frozen plasma

THROMBATE III delivers a naturally occurring, direct AT replacement that can be readily available at the point of care. Each vial provides predictable dosing, with a concentrated low volume.

IMPORTANT SAFETY INFORMATION


THROMBATE III® (antithrombin III [human]) is indicated in patients with hereditary antithrombin deficiency for treatment and prevention of thromboembolism and for prevention of perioperative and peripartum thromboembolism.

Hypersensitivity reactions may occur. Should evidence of an acute hypersensitivity reaction be observed, promptly interrupt the infusion and begin appropriate treatment.

Because THROMBATE III is made from human blood, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. There is also the possibility that unknown infectious agents may be present in the product.

Perform coagulation tests to avoid excessive or insufficient anticoagulation and monitor for bleeding or thrombosis. Measure functional plasma AT levels with amidolytic or clotting assays; do not use immunoassays.

In clinical studies, the most common adverse reactions (≥ 5% of subjects) were dizziness, chest discomfort, nausea, dysgeusia, and pain (cramps).

The anticoagulant effect of heparin is enhanced by concurrent treatment with THROMBATE III in patients with hereditary AT deficiency. Thus, in order to avoid bleeding, the dosage of heparin (or low molecular weight heparin) may need to be reduced during treatment with THROMBATE III.

Please see full Prescribing Information for THROMBATE III.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch, or call 1-800-FDA-1088.

References: 1. THROMBATE III® (antithrombin III [human]) Prescribing Information. Grifols. 2. Hellgren M, Tengborn L, Abildgaard U. Gynecol Obstet Invest. 1982;14(2):127-141. 3. Franchini M, Veneri D, Salvagno GL, Manzato F, Lippi G. Crit Rev Clin Lab Sci. 2006;43(3):249-290.